Edwin M. Posadas

Mar 28, 2024 | obroncology.com | Edwin M. Posadas |Robert A. Figlin

The treatment of biochemical recurrence in prostate cancer “is set for rapid development over the next few years,” says Edwin M. Posadas, MD, medical director of the Center for Uro-Oncology Research Excellence at the Samuel Oschin Comprehensive Cancer Center at Cedars-Sinai Medical Center in Los Angeles. Data from the recent EMBARK trial have changed practice for the treatment of men with high-risk features. Dr. Posadas discusses these findings and related advances with Robert A.

Mar 14, 2024 | urotoday.com | Edwin M. Posadas

Read the Full Video TranscriptZach Klaassen: Hi, my name is Dr. Zach Klaassen. I'm a urologic oncologist at the Georgia Cancer Center in Augusta, Georgia. And I'm pleased to be joined today by Dr. Edwin Posadas, who is a medical oncologist at Cedars-Sinai Medical Center in Los Angeles, California. Thanks so much for joining us today, Dr. Posadas. Edwin Posadas: Hi, I'm glad to be here. Thank you for the invitation. Zach Klaassen: Absolutely.

Dec 18, 2023 | obroncology.com | Edwin M. Posadas |Robert A. Figlin

From the use of prostate-specific membrane antigen positron-emission tomography to advancements in targeted treatments, prostate cancer care is quickly evolving. Edwin M. Posadas, MD, director of the Experimental Therapeutics Program and medical director of the Center for Uro-Oncology Research Excellence at Cedars-Sinai in Los Angeles, speaks with Robert A.

May 24, 2023 | onclive.com | Alan Bryce |Elisabeth I. Heath |Benjamin H. Lowentritt |Chesapeake Urology |Edwin M. Posadas |Tian Zhang

OncologyLiveOncology FellowsSupplements And Featured PublicationsAll Publications

May 17, 2023 | onclive.com | Alan Bryce |Elisabeth I. Heath |Benjamin H. Lowentritt |Chesapeake Urology |Edwin M. Posadas |Tian Zhang

OncologyLiveOncology FellowsSupplements And Featured PublicationsAll Publications